Guangdong Hybribio Biotech: Market Snapshot and Contextual Performance
Guangdong Hybribio Biotech (300639.SZ) closed the trading session on Thursday, 22 October 2026, at a level that left its price unchanged for the 24‑hour period ending at 22:34 Central Europe time. The share price was recorded at CNY 5.73, matching the price of the prior day and indicating a flat 0 % change.
The company’s current market capitalisation stands at CNY 3.9 billion. Over the last 24 hours, approximately CNY 126.4 million worth of shares changed hands, a modest volume relative to the 644.3 million shares that remain available in the market. A simple moving average (SMA) over the past 200 days is CNY 5.70, suggesting that the stock has traded above its long‑term average price, a possible indicator of sustained investor confidence.
The 52‑week high reached CNY 10.07 on 28 January 2026, while the 52‑week low fell to CNY 4.75 on 29 June 2026. The current trading price sits roughly midway between these extremes, implying a moderate level of volatility for the year to date.
In comparison with peer companies, Guangdong Hybribio’s performance has been notably stable. All five comparables listed below have experienced a flat 0 % change over the same 24‑hour period:
| Stock | Current Price (CNY) | Market Capitalisation (CNY) | P/E Ratio |
|---|---|---|---|
| Shandong Mining Machinery (002526.SZ) | 2.70 | 4.7 bn | 152.02 |
| Heilongjiang Zbd Pharmaceu (603567.SS) | 4.86 | 4.7 bn | – |
| Shanghai Shenda (600626.SS) | 3.52 | 4.7 bn | 49.04 |
| Shanghai Zhongzhou Special (300963.SZ) | 9.98 | 4.7 bn | 76.05 |
| Shanghai Kinetic Medical C (300326.SZ) | 6.70 | 4.7 bn | 21.41 |
While the majority of these companies are also trading flat, Shanghai Kinetic Medical C has highlighted a positive outlook for its forthcoming fiscal year. The company anticipates gains in both raw‑material and innovative drug segments, supported by expanded global sales channels and accelerated product launches. Its strategy to invest in research and development is projected to sustain upward earnings momentum.
About Guangdong Hybribio Biotech
Guangdong Hybribio Biotech Co., Ltd. is a biotechnology firm headquartered in Sheung Wan, Hong Kong, with a primary listing on the Shenzhen Stock Exchange. The company focuses on the research, development, manufacture, sale, and after‑sales support of in‑vitro diagnostic (IVD) products.
Key product categories include:
- HPV and sexually transmitted disease kits
- Thalassemia and prenatal neonatal testing kits
- Female sample collection kits
- DNA extraction kits (e.g., hepatitis B real‑time PCR)
- Diagnostic devices such as flow‑through hybridization systems, auto DNA extractors, and fluorescent quantitative detection instruments
These products serve hospitals, medical institutes, and large‑scale screening programmes worldwide. Guangdong Hybribio maintains a broad geographic footprint, with operations spanning the Asia Pacific, Southeast Asia, the Middle East, Europe, Africa, and South America.
For further information, the company’s official website is www.hybribio.cn .
